Program
Pyridoxine
Also written as “Doxylamine + Pyridoxine” and “Vitamin B12, Vitamin B6, Folic acid”.
Its studies are mostly in Nausea · Vitamin B 12 Deficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Valenta Pharm JSC | 20 open or running | phase 1since Mar 11, 2024 | Aug 9, 2022 | none ahead |
| Medice Arzneimittel Pütter GmbH & Co KG | 10 open or running | phase 4since May 1, 2025 | May 1, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 9, 2022First study: no phase study in NauseaNew to Valenta Pharm JSCValenta Pharm JSC · NCT05498233 · 28 enrolled · Russian Federation
- Mar 11, 2024Phase 1 study in NauseaValenta Pharm JSC · NCT06342778 · 28 enrolled · Russia
- May 1, 2025Medice Arzneimittel Pütter GmbH & Co KG's first study: phase 4 study in Vitamin B 12 DeficiencyNew to Medice Arzneimittel Pütter GmbH & Co KGMedice Arzneimittel Pütter GmbH & Co KG · NCT07029698 · 46 enrolled · Ukraine
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07029698Vitamin B 12 Deficiency · Ukraine | 4 | Completed | Medice Arzneimittel Pütter GmbH & Co KG | Oct 7, 2025 | 46 |
| NCT06342778Nausea · Russia | 1 | Completed | Valenta Pharm JSC | May 2, 2024 | 28 |
| NCT05498233Nausea · Russian Federation | – | Completed | Valenta Pharm JSC | Sep 19, 2022 | 28 |
How it is read
Names in the registry
- “Doxylamine + Pyridoxine”, 2 entries
- “Vitamin B12, Vitamin B6, Folic acid”, 1 entry
Conditions, from the studies’ own filings
- Nausea, 2 studies
- Vitamin B 12 Deficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.